The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) is a huge mover today! About 81,827 shares traded hands. Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has declined 31.76% since April 4, 2016 and is downtrending. It has underperformed by 32.85% the S&P500.
The move comes after 8 months positive chart setup for the $256.44M company. It was reported on Nov, 4 by Barchart.com. We have $17.86 PT which if reached, will make NASDAQ:PRTK worth $151.30M more.
Analysts await Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to report earnings on November, 10. They expect $-1.34 EPS, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.69 actual EPS reported by Paratek Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -20.71% EPS growth.
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Ratings Coverage
Out of 6 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Paratek Pharmaceuticals has been the topic of 10 analyst reports since July 23, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained Paratek Pharmaceuticals Inc (NASDAQ:PRTK) rating on Friday, June 17. H.C. Wainwright has “Buy” rating and $34 price target. The company was initiated on Friday, May 13 by Robert W. Baird. The company was initiated on Thursday, July 23 by Gabelli. The stock has “Buy” rating given by Ladenburg Thalmann on Friday, June 17. On Saturday, August 8 the stock rating was downgraded by Zacks to “Hold”. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Hold” rating by Zacks on Wednesday, September 2. Zacks downgraded the shares of PRTK in a report on Saturday, August 22 to “Hold” rating. Zacks upgraded the shares of PRTK in a report on Tuesday, September 22 to “Hold” rating. The firm has “Outperform” rating given on Thursday, October 27 by Leerink Swann. The firm earned “Sell” rating on Friday, August 14 by Zacks.
According to Zacks Investment Research, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.”
Insitutional Activity: The institutional sentiment increased to 5.42 in 2016 Q2. Its up 4.27, from 1.15 in 2016Q1. The ratio improved, as 5 funds sold all Paratek Pharmaceuticals Inc shares owned while 7 reduced positions. 28 funds bought stakes while 37 increased positions. They now own 29.25 million shares or 145.06% more from 11.93 million shares in 2016Q1.
Opus Point Prns Mgmt Ltd holds 0.51% or 37,665 shares in its portfolio. Numeric Limited Liability Com holds 0.04% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 311,655 shares. Granite Inv Partners Limited Liability Corporation reported 47,776 shares or 0.05% of all its holdings. General Amer last reported 0.69% of its portfolio in the stock. Financial Bank Of America De has 8,322 shares for 0% of their US portfolio. Highland Cap Management L P last reported 0.04% of its portfolio in the stock. Rhumbline Advisers has 13,792 shares for 0% of their US portfolio. Schwab Charles Investment Management Incorporated, a California-based fund reported 25,108 shares. Credit Suisse Ag accumulated 0% or 10,635 shares. Senzar Asset Mngmt Ltd Company has invested 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Morgan Stanley has 0% invested in the company for 13,849 shares. Point72 Asset Ltd Partnership last reported 100,000 shares in the company. Blackrock Fund Advisors has 0% invested in the company for 373,419 shares. Stoneridge Invest Prtn Limited Company reported 23,668 shares or 0.05% of all its holdings. , a New York-based fund reported 8,297 shares.
More news for Paratek Pharmaceuticals Inc (NASDAQ:PRTK) were recently published by: Globenewswire.com, which released: “Paratek Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and …” on November 02, 2016. Finance.Yahoo.com‘s article titled: “Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) to Ring The Nasdaq Stock Market …” and published on October 03, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.